ETC120

**ETC120** is an investigational, plant-derived oral cannabinoid oil developed for chronic insomnia disorder. It is a fixed-dose formulation of **10 mg delta-9-tetrahydrocannabinol** and **200 mg cannabidiol** per 2 mL dose, suspended in medium-chain triglycerides oil. THC engages cannabinoid receptors, principally cannabinoid receptor 1 and cannabinoid receptor 2, while CBD may modulate endocannabinoid signaling through a distinct and pharmacologically broad mechanism. ETC120 was evaluated in the randomized, double-blind, placebo-controlled CANSLEEP crossover proof-of-concept study for effects on polysomnographic sleep measures, brain activity, cognition, alertness, and simulated driving performance in adults with chronic insomnia disorder. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619000714189))